Navigation Links
Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation
Date:2/6/2012

s are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death. 

Presently, the only product approved for the treatment of acute repetitive seizures outside of the hospital setting, is a rectally administered formulation of diazepam called Diastat®.  Because of its rectal mode of administration, Diastat® has been primarily relegated to use in younger pediatric patients (usually less than 10 years of age).  The majority of patients with acute repetitive seizures; however, are currently seen in emergency rooms and treated with intravenous benzodiazepines.  Most of these patients are admitted to the hospital.  This represents a significant component of the estimated $15 billion annual economic burden on the system to treat epilepsy in the U.S.  Intranasal diazepam would provide a more convenient alternative to either rectal administration of Diastat® or the need to visit the emergency room for intravenous administration of drugs.

About Neurelis

Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: David F. Hale
858-756-2480
Email: salaimo@neurelis.com

 

 

 


'/>"/>
SOURCE Neurelis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
3. Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam
4. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
5. Genomic Health Announces Formation of New Genetics Subsidiary
6. Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay - Harmony Prenatal Test™ - and Publication of Study on Specimen Transport
7. Amrita Hospital Information System Announces its First Hospital Meaningful Use Attestation!
8. InspireMD Announces Positive Clinical Data From Trial of MGuard™
9. Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Companys Synthetic Biologics Strategic Focus
10. Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
11. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 The nation,s newest Actos ... Las Vegas courtroom.  Attorneys representing two ... men suffered severe effects, including death, after using the diabetes ... what they as a company knew, that their drug Actos ... Robert Eglet .  "In order to hold Takeda responsible it ...
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
(Date:8/28/2015)... ... ... External Counterpulsation, also known as ECP or EECP, is a proven treatment ... ECP) machines with a full clinic licence to help people prevent and reverse heart ... prevent and reverse heart disease through its evidence-based integrative approach to heart ...
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and ... and pleads for swift actions to be taken in order to ease the ... , Yisrayl says scientists have yet to understand fully the real cause of global ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life ... of the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and ... over the last three years, PREVENT ranks higher on the list than any other ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... may be beneficial in preventing severe long-term disability in multiple ... treatment for the chronic progressive phase of MS, when serious ... Children's Hospital Boston study appearing in the Journal of Neuroscience, ... type of vitamin B3 known as nicotinamide cut the risk ...
... help reduce Alzheimer's disease, says a study on mice, but ... findings apply to people.// ,Jun Wang and other researchers ... mice with genes that order the production of amyloid-beta protein, ... reported the online edition of science magazine WebMD. ...
... the basic purpose of a sunscreen lotion as well as ... well on the threshold of a discovery; Scientists have found ... the fair skin people from tanning as well as guard ... David E. Fisher, director of the Melanoma Program at the ...
... 80% of people suffering from severe chronic lung disease ... of it.// ,Chronic Bronchitis and Emphysema constitute the ... lung tissue by smoking can lead to the development ... ,Professor Robert West, director of tobacco studies at Cancer ...
... particularly those with high levels of low-density lipoprotein ... according to a study in the September 20 ... specific class of lipoprotein particles found in human ... according to background information in the article. Studies ...
... kidney cancer has been rising over the last two decades, ... Center shows// that this increase is driven largely by the ... the rising incidence has been paralleled by greater use of ... fewer people dying. ,“With increased early detection and treatment ...
Cached Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:80% of lung disease remains ‘undiagnosed’. 2Health News:High Levels of Lipoprotein(a) in Women is Associated With Cardiovascular Risk 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 3
The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
... The Invacare Digital Pulse ... and pulse strength. It is ... measurements on challenging patients. The ... other artifacts, informs the operator ...
Rad-9™...
Medicine Products: